Measurement of Retinal Nerves and Blood Vessels as Markers for Type 1 Diabetes

项目摘要/摘要 目前非常需要新的非侵入式成像技术 用于1型糖尿病并发症早期检测、诊断和量化的生物标志物 (T1D)如糖尿病视网膜病变(DR)。物理科学公司(PSI)建议开发一种成像 基于改装成现有高分辨率视网膜成像的新检测装置的平台 包括自适应光学辅助扫描激光眼底镜(AO-SLO)和光学的平台 相干断层扫描(OCT)。这项新技术将允许血液的可视化和量化 血管结构和神经束排列，由AO提供精致的细节。建议数 检测方案将首先使用现有的多模式光学视网膜成像仪进行测试和演示 (毛利语)在第一阶段，然后在第二阶段，将专门为成像开发新的毛利人原型 糖尿病引起的视网膜改变的特殊特征。T1D的特异性生物标志物 并发症的定义将基于我们的合作者从波士顿儿童医院获得的患者数据 医院。在第二阶段计划期间，将对大约40名不同阶段的DR患者进行成像。 PSI在开发和商业化高分辨率视网膜成像仪方面有着悠久而成功的历史 眼科研究市场。PSI和我们的合作者已经认识到，主要的 发展AO-SLO临床市场的障碍是，很少有深入的研究 声学造影仪在疾病诊断和治疗效果跟踪中的医学应用。 尽管有相对较多的关于AO的好处的研究出版物 视力的基本方面，到目前为止，AO还没有在临床市场上获得吸引力。然而，鉴于 神经血管疾病发病率大，有可能建议应用高- 分辨率视网膜成像研究糖尿病引起的视网膜变化将产生巨大的驱动力 使AO更接近临床市场。因此，PSI正在申请资金来开发这项技术 可能会对视觉研究以及随后的临床诊断和 对DR的管理。

Project Summary/Abstract There is currently a significant need for new non-invasive imaging techniques able to accurately quantify biomarkers for early detection, diagnosis, and quantification of complications in type 1 diabetes (T1D) such as diabetic retinopathy (DR). Physical Sciences Inc. (PSI) proposes to develop an imaging platform based on a new detection arrangement retrofitted to an existing high-resolution retinal imaging platform that includes adaptive optics-assisted scanning laser ophthalmoscopy (AO-SLO) and Optical Coherence Tomography (OCT). The new technique will allow for visualization and quantification of blood vessels structure and nerve bundle arrangement with exquisite details afforded by AO. The proposed detection scheme will be first tested and demonstrated using an existing multimodal AO retinal imager (MAORI) in Phase I and then in Phase II a new MAORI prototype will be developed specifically for imaging particular characteristics of retinal alterations induces by diabetes. Specific biomarkers for T1D complications will be defined based on patient data acquired by our collaborators from Boston Children's Hospital. About 40 patients with different stages of DR will be imaged during the Phase II Program. PSI has a long, successful history of developing and commercializing high-resolution retinal imagers for the ophthalmic research market. PSI and our collaborators have recognized that one of the main impediments in developing a clinical market for AO-SLO's is that there have been few in-depth studies on the medical application of AO imagers for disease diagnosis and tracking the efficacy of treatments. Despite a relatively large number of research publications on the benefits of AO on understanding fundamental aspects of vision, so far AO has not gained traction in the clinical market. However, given the large incidence of neurovascular diseases, it is possible that the proposed application to use high- resolution retinal imaging to investigate the retinal changes due to diabetes will generate significant drive to bring AO closer to the clinical market. Therefore, PSI is requesting funding for developing this technology with a potentially significant impact on vision research and subsequently on the clinical diagnosis and management of DR.